Literature DB >> 8170479

The rat probasin gene promoter directs hormonally and developmentally regulated expression of a heterologous gene specifically to the prostate in transgenic mice.

N M Greenberg1, F J DeMayo, P C Sheppard, R Barrios, R Lebovitz, M Finegold, R Angelopoulou, J G Dodd, M L Duckworth, J M Rosen.   

Abstract

An expression cassette carrying 426 basepairs of the rat probasin (PB) gene promoter and 28 basepairs of 5'-untranslated region is sufficient to target the expression of the bacterial chloramphenicol acetyltransferase (CAT) gene specifically to the prostate in transgenic mice. The PB-CAT transgene was expressed in three of five (60%) independent lines of mice, and this expression, as reported previously for the endogenous rat gene, was male specific, restricted primarily to the lateral, dorsal, and ventral lobes of the prostate, with only very low levels of CAT activity detected in the anterior prostate and seminal vesicles. The developmental and hormonal regulation of the transgene also paralleled that reported for the rat gene, with a 70-fold increase in CAT activity in the mouse prostate observed between 2-7 weeks of age, a time corresponding to sexual maturation. PB-CAT activity in the prostate declined after castration to 3.5% of the precastration level, and the CAT activity in castrated males approached precastration levels when mice were supplemented with testosterone. Transgene expression in castrated males was not induced by dexamethasone. Coinjection of PB-CAT with a chicken lysozyme gene matrix attachment region resulted in their cointegration and further restricted the pattern of PB-CAT to the dorsolateral prostate, with suppressed expression observed in the ventral prostate. These studies demonstrate that a minimal rat probasin promoter can target heterologous gene expression specifically to the prostate in a developmentally and hormonally regulated fashion.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8170479     DOI: 10.1210/mend.8.2.8170479

Source DB:  PubMed          Journal:  Mol Endocrinol        ISSN: 0888-8809


  74 in total

1.  Foxa2 activates the transcription of androgen receptor target genes in castrate resistant prostatic tumors.

Authors:  Zachary M Connelly; Shu Yang; Fenghua Chen; Yunshin Yeh; Nazih Khater; Renjie Jin; Robert Matusik; Xiuping Yu
Journal:  Am J Clin Exp Urol       Date:  2018-10-20

2.  Identification and characterization of a prostate-specific androgen-independent protein-binding site in the probasin promoter.

Authors:  Lillian H Y Yeung; Jason T Read; Pernille Sorenson; Colleen C Nelson; William Jia; Paul S Rennie
Journal:  Biochem J       Date:  2003-05-01       Impact factor: 3.857

3.  Ron receptor overexpression in the murine prostate induces prostate intraepithelial neoplasia.

Authors:  Jerilyn K Gray; Andrew M Paluch; William D Stuart; Susan E Waltz
Journal:  Cancer Lett       Date:  2011-09-24       Impact factor: 8.679

4.  Silibinin inhibits established prostate tumor growth, progression, invasion, and metastasis and suppresses tumor angiogenesis and epithelial-mesenchymal transition in transgenic adenocarcinoma of the mouse prostate model mice.

Authors:  Rana P Singh; Komal Raina; Girish Sharma; Rajesh Agarwal
Journal:  Clin Cancer Res       Date:  2008-12-01       Impact factor: 12.531

5.  Growth, regeneration, and tumorigenesis of the prostate activates the PSCA promoter.

Authors:  Tetsuro Watabe; Mark Lin; Hisamitsu Ide; Annemarie A Donjacour; Gerald R Cunha; Owen N Witte; Robert E Reiter
Journal:  Proc Natl Acad Sci U S A       Date:  2001-12-18       Impact factor: 11.205

6.  Multiple signal input and output domains of the 160-kilodalton nuclear receptor coactivator proteins.

Authors:  H Ma; H Hong; S M Huang; R A Irvine; P Webb; P J Kushner; G A Coetzee; M R Stallcup
Journal:  Mol Cell Biol       Date:  1999-09       Impact factor: 4.272

7.  Expression of conditional cre recombinase in epithelial tissues of transgenic mice.

Authors:  Fang Wen; Grace Cecena; Varinia Munoz-Ritchie; Elaine Fuchs; Pierre Chambon; Robert G Oshima
Journal:  Genesis       Date:  2003-02       Impact factor: 2.487

8.  A FOXA1-binding enhancer regulates Hoxb13 expression in the prostate gland.

Authors:  Ryan P McMullin; Albert Dobi; Laura N Mutton; András Orosz; Shilpi Maheshwari; Cooduvalli S Shashikant; Charles J Bieberich
Journal:  Proc Natl Acad Sci U S A       Date:  2009-12-14       Impact factor: 11.205

9.  CTLA-4 blockade synergizes with tumor-derived granulocyte-macrophage colony-stimulating factor for treatment of an experimental mammary carcinoma.

Authors:  A A Hurwitz; T F Yu; D R Leach; J P Allison
Journal:  Proc Natl Acad Sci U S A       Date:  1998-08-18       Impact factor: 11.205

10.  Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2.

Authors:  Aparna Gupta; Xiuping Yu; Tom Case; Manik Paul; Michael M Shen; Klaus H Kaestner; Robert J Matusik
Journal:  Prostate       Date:  2012-10-11       Impact factor: 4.104

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.